Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.

Rosenberg JE, Mamtani R, Sonpavde GP, Loriot Y, Duran I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Sridhar SS, Pappot H, Gurney H, Bedke J, van der Heijden MS, Galli L, Keam B, Masumori N, Meran J, O'Donnell PH, Park SH, Grande E, Sengeløv L, Uemura H, Skaltsa K, Campbell M, Matsangou M, Wu C, Hepp Z, McKay C, Powles T, Petrylak DP

Open source

DOI: 10.1016/j.eururo.2024.01.007
Published: 2024 Jun
Container: European urology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.eururo.2024.01.007,
  title = {Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.},
  author = {Rosenberg JE and Mamtani R and Sonpavde GP and Loriot Y and Duran I and Lee JL and Matsubara N and Vulsteke C and Castellano D and Sridhar SS and Pappot H and Gurney H and Bedke J and van der Heijden MS and Galli L and Keam B and Masumori N and Meran J and O'Donnell PH and Park SH and Grande E and Sengeløv L and Uemura H and Skaltsa K and Campbell M and Matsangou M and Wu C and Hepp Z and McKay C and Powles T and Petrylak DP},
  year = {2024},
  journal = {European urology},
  doi = {10.1016/j.eururo.2024.01.007},
  url = {https://doi.org/10.1016/j.eururo.2024.01.007}
}

RIS

TY  - JOUR
TI  - Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.
AU  - Rosenberg JE
AU  - Mamtani R
AU  - Sonpavde GP
AU  - Loriot Y
AU  - Duran I
AU  - Lee JL
AU  - Matsubara N
AU  - Vulsteke C
AU  - Castellano D
AU  - Sridhar SS
AU  - Pappot H
AU  - Gurney H
AU  - Bedke J
AU  - van der Heijden MS
AU  - Galli L
AU  - Keam B
AU  - Masumori N
AU  - Meran J
AU  - O'Donnell PH
AU  - Park SH
AU  - Grande E
AU  - Sengeløv L
AU  - Uemura H
AU  - Skaltsa K
AU  - Campbell M
AU  - Matsangou M
AU  - Wu C
AU  - Hepp Z
AU  - McKay C
AU  - Powles T
AU  - Petrylak DP
PY  - 2024
JO  - European urology
DO  - 10.1016/j.eururo.2024.01.007
UR  - https://doi.org/10.1016/j.eururo.2024.01.007
ER  -

APA

JE, R., R, M., GP, S., Y, L., I, D., JL, L., N, M., C, V., D, C., SS, S., H, P., H, G., J, B., MS, V. D. H., L, G., B, K., N, M., J, M., PH, O., SH, P., E, G., L, S., H, U., K, S., M, C., M, M., C, W., Z, H., C, M., T, P., & DP, P. (2024). Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.. European urology. https://doi.org/10.1016/j.eururo.2024.01.007

Source records

pubmed · retrieved 2026-09-26T17:36:24.870Z